Antiplatelet Aggregating Agents

  • M. R. P. Hall
Part of the Ettore Majorana International Science Series book series (PSLI)


Arterial or venous occlusion by blood clot are common occurrences in old age and the incidence rises as age progresses. They both give rise to considerable morbidity as well as mortality. The prevention of thrombosis and its consequences would inevitably promote and maintain health in old people. To attempt to do this is a worthy cause and it is not surprising that many people have set out along this road with much enthusiasm, but often little planning.


Platelet Aggregation Inhibit Platelet Function Thromboxane Synthetase Thrombin Induce Platelet Aggregation Anturan Reinfarction Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. B. Wright, Geriatric diagnosis - a survey, Geront.Clin. 11: 75 (1969).CrossRefGoogle Scholar
  2. 2.
    E. de Brito Paiva, J. Borgykowski, and J. P. Junod, Physiotherapeutic prophylaxis of pulmonary embolism in the elderly high risk patient: Indications and limitations, J.Clin. Exp.Geront. 3: 245 (1981).Google Scholar
  3. 3.
    F. I. Pareti, P. M. Mannucci, Drugs affecting platelet behaviour, J.Roy.Coll.Phycns. 10: 194 (1976).Google Scholar
  4. 4.
    H. J. Weiss, Antiplatelet drugs - a new pharmacologic approach to the prevention of thrombosis, Am.Heart J. 92: 86 (1976).CrossRefGoogle Scholar
  5. 5.
    G. de Gaetano, C. Cerletti, and V. Bertele, Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link, Lancet 2: 974 (1982).CrossRefGoogle Scholar
  6. 6.
    J. R. A. Mitchell, Anticoagulants in coronary heart disease - retrospect and prospect, Lancet 1: 257 (1981).CrossRefGoogle Scholar
  7. 7.
    M. L. Steer, and E. W.I.Salzman, Cyclic nucleotides in hemostasis and thrombosis, in: “Advances in Cyclic Nucleotide Research, P. Hamer and H. Sands, eds., Vol. 12, Raven Press, New York (1980).Google Scholar
  8. 8.
    S. Moncada, and R. Korbut, Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin, Lancet 1: 1286 (1978).CrossRefGoogle Scholar
  9. 9.
    J. Vermylen, G. Defreyn, L. O. Carreras, S. J. Machin, J. Van Schaeren,. and M. Verstraete, Thromboxane synthetase inhibition as antithrombotic strategy, Lancet 1: 1073 (1981).CrossRefGoogle Scholar
  10. 10.
    E. J. Hornby, and I. F. Skidmore, Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production, Biochem.Pharm. 31: 1158 (1982).CrossRefGoogle Scholar
  11. 11.
    V. Bertele, C. Cerletti, A. Schieppati, G. Di Minno, G. de Gaetano, Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation, Lancet 1: 1057 (1981).CrossRefGoogle Scholar
  12. 12.
    C. Cerletti, M. Livio, and G. de Gaetano, Non-steroidal antiinflammatory drugs react with two sites on platelet cyclooxygenase. Evidence from in vivo drug interaction studies in rats, Biochem.B ophys.Acta. 714: 122 (1982).CrossRefGoogle Scholar
  13. 13.
    H. A. Smythe, M. A. Ogryzlo, E. A. Murphy, and J. F. Mustard, The effect of sulphinpyrazone (Anturan) on platelet economy and blood coagulation in man, Can.Med.Assoc.J. 92: 818 (1965).Google Scholar
  14. 14.
    J. R. O′Brien, Effects of salicylates on human platelets, Lancet 1: 779 (1968).CrossRefGoogle Scholar
  15. 15.
    S. P. Hanley, J. Bevan, S. R. Cockbill, and S. Heptinstall, Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis, Lancet 1: 969 (1981).CrossRefGoogle Scholar
  16. 16.
    Anturan Reinfarction Trial Research Group, Sulphznpyrazone in the prevention of sudden death after myocardial infarction, N.Eng.J.Med. 302: 250 (1980).CrossRefGoogle Scholar
  17. 17.
    Anturan Reinfarction Italian Study, Sulphinpyrazone in post-myocardial infarction, Lancet 1: 237 (1982).Google Scholar
  18. 18.
    The Persantir-Aspirin Reinfarction Study Research Group. Persantin and aspirin in coronary heart disease, Circulation 62: 449 (1980)Google Scholar
  19. 19.
    J. A. Blakely, and M. Gent, Platelets drugs and longevity in a geriatric population, in: “Platelets Drugs and Thrombosis,” J. Hirsh, J. F. Cade, A. S. Galius, eds., S. Karger, Basel (1975).Google Scholar
  20. 20.
    J. Acheson, G. Danta, and E. C. Hutchinson, Controlled trial of dipyridamole in cerebral vascular disease, 1:614 (1969).CrossRefGoogle Scholar
  21. 21.
    P. E. Hansen, J. H. Hansen, and S. Stenbjerg, Platelet aggregation in focal cerebral ischaemia: a clinical study. Acta Neurol.Scand: 65: 212 (1982).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • M. R. P. Hall
    • 1
  1. 1.Department of Geriatric MedicineSouthampton General HospitalSouthhamptonUSA

Personalised recommendations